Articles  |   September 2016
SEE Question
Article Information
Central and Peripheral Nervous Systems / Education / CPD / Pharmacology / Articles
Articles   |   September 2016
SEE Question
ASA Monitor 09 2016, Vol.80, 42-43.
ASA Monitor 09 2016, Vol.80, 42-43.
A recent study evaluated nitrous oxide as a therapy for treatment-resistant depression. Which of the following effects did investigators find?
Major depression is one of the most common psychiatric disorders. As many as one-third of patients with major depression have treatment-resistant depression (TRD), meaning they have failed to respond to multiple treatments of standard antidepressant medication.
Recently, ketamine has been utilized as a therapeutic agent for patients with TRD. Patients appear to achieve sustained response to intermittent dosing. In fact, the National Institute of Mental Health is currently conducting a dose-finding trial with ketamine (https://clinicaltrials.gov, Identifier NCT01920555). The purported mechanism of action of ketamine for the treatment of TRD is antagonism of the N-methyl-D-aspartate (NMDA) receptor.
First Page Preview
First page PDF preview
First page PDF preview ×
View Large
0 Comments
Submit a Comment
Submit A Comment

Contributors must reveal any conflict of interest. Comments are moderated.

Name
Affiliation & Institution
I have a potential conflict of interest
Comment Title
Comment


This feature is available to Subscribers Only
ASA Member Login or Create an Account ×